DRZ

About Daniel Zlatin

This author has not yet filled in any details.
So far Daniel Zlatin has created 145 blog entries.

BTK Degrader Trial Now Recruiting in Canada

2025-03-03T09:31:33-05:00

Clinical trial NCT05006716 of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader, is recruiting patients in Calgary, Edmonton, Québec, Vancouver, and Toronto.    Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies.  For more information, see the trial's description on the NIH website.

BTK Degrader Trial Now Recruiting in Canada2025-03-03T09:31:33-05:00

State of the art review of WM

2025-03-03T09:26:05-05:00

Two journal article provide an end-to-end review of WM.  Co-authored by experts from the Dana-Farber Cancer Institute, they are highly recommended to all practitioners. Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems is available at https://www.mjhid.org/mjhid/article/view/5732/4535 Part 2: Focus on Therapy is available at https://www.mjhid.org/mjhid/article/view/5878/4639  

State of the art review of WM2025-03-03T09:26:05-05:00

BTK Degrader Trial Now Recruiting in Canada

2025-03-02T11:35:08-05:00

Canadians with Waldenström’s Macroglobulinemia who meet inclusion requirements may want to consider participation in a new study of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader.  To help in your understanding of a BTK Degrader, see our recent post comparing them to BTK inhibitors (BTKi). Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies. Canadian Study Locations Now Recruiting: Calgary, AB:  Arthur Child Comprehensive Cancer Centre Edmonton, AB:  Cross Cancer Institute Québec, QC:  Université de Laval, Hôpital de l’enfant Jésus, Centre Integre de Cancerologie Vancouver, [...]

BTK Degrader Trial Now Recruiting in Canada2025-03-02T11:35:08-05:00

BTK Inhibitors vs. BTK Degraders

2025-02-18T21:02:53-05:00

Bruton’s tyrosine kinase (BTK) inhibitors and BTK Degraders are two different approaches to targeting BTK, a key enzyme in the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of B-cells. Both strategies are used in the treatment of B-cell malignancies and autoimmune diseases, but they operate through distinct mechanisms. BTK Inhibitors Mechanism of Action:  Inhibition.  BTK inhibitors are small molecules that bind to the active site of BTK, preventing its phosphorylation (a biological reaction in which phosphate is added to an organic molecule) and subsequent activation. This inhibits downstream signaling pathways that are essential for B-cell proliferation [...]

BTK Inhibitors vs. BTK Degraders2025-02-18T21:02:53-05:00

Winter Newsletter: Quality of Life is so important!!

2025-02-17T18:17:34-05:00

All our doctors agree -- Quality of Life is so important to WMers! Learn in our winter newsletter about resources available to you that can improve your Quality of Life: Look at what the Research shows Check out the IWMF Wellness Program -- a magnificent resource Meet Others Who Have Improved their Quality of Life Seek and Find Community Support Manage the Side-effects of Treatment with Good Nutrition Happy reading!

Winter Newsletter: Quality of Life is so important!!2025-02-17T18:17:34-05:00

Abstracts from IWWM-12 and ASH

2024-12-09T06:32:58-05:00

From the science desk, a report on: The 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) that took place in Prague, Czech Republic from October 17-19, 2024 where leading experts gathered to discuss the latest advances in the understanding and treatment of WM, and The 66th annual meeting and exposition of the American Society of Hematology (ASH) that took place in San Diego, California from December 7-10, 2024. The WMFC reviewed all of the IWWM-12 abstracts submitted in Prague and found that very many of the presentations/posters simply confirmed the work of others.  For example, several abstracts confirmed three WM lineages: B [...]

Abstracts from IWWM-12 and ASH2024-12-09T06:32:58-05:00

Dr. Shirley D’Sa on Bing Neel and Neuropathy

2024-11-18T15:39:08-05:00

The WMFC was delighted to be able to bring you Dr. Shirley D'Sa from University College London (UK) Hospitals.  She presented to us on Friday Nov. 15th, 2024. Dr. D'Sa discussed two topics: Peripheral Neuropathy (PN), a common condition experienced by people with WM. Bing-Neel Syndrome, a less-common complication of WM. For both of these, Dr. D'Sa addressed the symptoms of these conditions, how they develop, how you can enable a swift and accurate diagnosis and how it is recommended to treat these conditions. We came away understanding that Peripheral Neuropathy is far more complex than one might have thought and [...]

Dr. Shirley D’Sa on Bing Neel and Neuropathy2024-11-18T15:39:08-05:00

Check your Junk / Spam Folders!

2024-11-04T12:14:08-05:00

There have been changes in "the cloud" world recently, out of our control.  We're told that Google and other email organizations are tightening up their email filtering rules.  So emails from your WMFC might be ending up in your Junk or Spam email folders. And we hope you don't think they are either Junk or Spam! So please check your Junk and/or Spam folders to see if any recent emails from the WMFC have ended up in there.  If so, there might be some settings you can change so that email from any address ending in @wmfc.ca is not to be [...]

Check your Junk / Spam Folders!2024-11-04T12:14:08-05:00

Our September Newsletter

2024-09-26T18:34:18-04:00

The leaves have begun to change. And with that a variety of colourful subjects have been included in this newsletter’s topics, the first of which is “What’s up with WMFC in Canada?”, excerpts from a presentation by Cam Fraser to the board of the IWMF. And in other news articles, our September Newsletter covers “You’re Not Alone” WMFC Population Statistics from 2021 to 2024 What Your Heart Asks and Your Pocket Can Afford, by Anne Moffat, North Bay, Ontario Eastern Ontario Support Group Potluck Enjoy all of these titles in our September Newsletter available here!

Our September Newsletter2024-09-26T18:34:18-04:00

New WM Clinical Trial on the West Coast: Treatment Naive and R/R

2024-08-07T20:38:48-04:00

NCT05952037 (https://clinicaltrials.gov/study/NCT05952037) is using a new BCL-2 inhibitor, Sonrotoclax, and is strictly for WM patients.  The trial is world-wide, but is recruiting in just one location in Canada, in North Vancouver, at the Lions Gate Hospital Chemotherapy Clinic.  It has several arms running in parallel:  one is for treatment-naive patients; the other three are for Relapsed/Refractory patients with various treatment histories.

New WM Clinical Trial on the West Coast: Treatment Naive and R/R2024-08-07T20:38:48-04:00
Go to Top